Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Lymphoma

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leuk Lymphoma

Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL

doi: 10.1080/10428194.2025.2525982

Lymphoma

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Ann Oncol

Michot JM, Bologna S, Bastie JN, Borght TV, Brière J, Ribrag V, Bommier C, Peyrade F, Lebras L, Damaj G, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquières H, Fruchart C, Soussain C, Becker S, Olivier P, Julian A, Molina T, Haioun C, Tilly H

doi: 10.1016/j.annonc.2025.11.006

Further Publications

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

J Clin Oncol

Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ

doi: 10.1200/JCO-25-00507

Further Publications

Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis

Int J Cancer

Ouimet C, Rosu M, Kimmelman J

doi: 10.1002/ijc.70538

Lymphoma

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

J Clin Oncol

Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J

doi: 10.1200/JCO-25-01957

Further Publications

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Am J Hematol

Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, Sergentanis TN, Terpos E, Ntanasis-Stathopoulos I

doi: 10.1002/ajh.70201

Lymphoma

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Leuk Lymphoma

Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM

doi: 10.1080/10428194.2025.2604300

Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Blood

Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I

doi: 10.1182/blood.2025031733

Lymphoma

Early life environmental exposures and birth characteristics and childhood lymphoma risk: a systematic review and meta-analysis

J Natl Cancer Inst

Dolatkhah R, Onyije FM, Bouaoun L, Olsson A, Schüz J

doi: 10.1093/jnci/djag136

Related content

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Early life environmental exposures and birth characteristics and childhood lymphoma risk: a systematic review and meta-analysis